Add-on administration of ultramicronized palmitoylethanolamide in the treatment of new-onset burning mouth syndrome

Chirchiglia D, Chirchiglia P, Marotta R, Gallelli L. Int Med Case Rep J. 2019 Feb 15;12:39-42.

Case seriesHumans

Design

Case series

Subjects

One 60-year-old man with new-onset burning mouth syndrome

Dose used in the study

Ultramicronised PEA added to existing gabapentin therapy; PEA dose not stated in the abstract

Duration

3 months

What was measured

Pain, using a Visual Analog Scale (VAS)

What the authors reported

Gabapentin alone gave poor symptom control, with a VAS score of 8-9. After adding umPEA, pain frequency and intensity improved over 3 months, with the VAS score falling to 5. Brain CT/MRI and laboratory tests were normal throughout.

Limits of this study

A single case report with add-on treatment, so PEA's own contribution cannot be separated from gabapentin or natural change. The authors report no conflicts of interest.

Source

PubMed 30858732 · doi:10.2147/IMCRJ.S194403

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.